Inhibition of the actions of peroxisome proliferator-activated receptor a on obesity by estrogen

Obesity

Volumn 15, Issue 6, 2007, Pages 1430-1440

  Jeong, Sunhyo ^a   Yoon, Michung ^a  

^a Mokwon University   (South Korea)

Author keywords

Estrogen; Lipid metabolism; Peroxisome proliferator activated; Women

Indexed keywords

ANTILIPEMIC AGENT; DNA BINDING PROTEIN; ESTRADIOL; FENOFIBRATE; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; LIPID METABOLISM; LIVER; METABOLISM; MOUSE; OBESITY; PHYSIOLOGY; REPORTER GENE;

ADIPOSITY; ANIMALS; ANTILIPEMIC AGENTS; BODY WEIGHT; CELLS, CULTURED; DNA-BINDING PROTEINS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; LIPID METABOLISM; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; OBESITY; PPAR ALPHA; PROCETOFEN; TRANSFECTION;

MUS;

EID: 34547185555     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.171     Document Type: Article

References (48)

1. Schoonjans K, Staels B, Auwerx J. Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 2000;37:907-25.
2. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrate on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-93.
3. Kliewer SA, Lehmann JM, Wilson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science. 1999;30:757-60.
4. Sander K, Beatrice D, Walter W. Roles of PPARs in health and disease. Nature. 2000;405:421-4.
5. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-III. J Biol Chem. 1995;270:13470-5.
6. Auwerx J, Schoonjans K, Fruchart JC, Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis. 1996;124:S29-37.
7. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336-48.
8. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem. 1997;272: 28210-7.
9. Zhang B, Marcus SL, Sajjadi FG, et al. Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci U S A.1992;89:7541-5.
10. Osumi T, Osada S, Tsukamoto T. Analysis of peroxisome proliferator-responsive enhancer of the rat acyl-CoA oxidase gene. Ann N Y Acad Sci. 1996;804:202-13.
11. Nicolas-Frances V, Dasari VK, Abruzzi E, Osumi T, Latrufle N. The peroxisome proliferator response element (PPRE) present at positions -681/-669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally interacts differently with PPARalpha and HNF-4. Biochem Biophys Res Commun. 2000;269-.347-51.
12. Bourgeois F, Alexiu A, Lemonnier D. Dietary-induced obesity: effect of dietary fats on adipose tissue cellularity in mice. Br J Nutr. 1983;49:17-26.
13. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998;273: 29577-85.
14. Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000;271:445-50.
15. Guerre-Millo M, Gervois P, Raspe E, et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000;275: 16638-42.
16. Mancini FP, Lanni A, Sabatino L, et al. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 2001;491:154-8.
17. Mystkowski P, Schwartz MW. Gonadal steroids and energy homeostasis in the leptin era. Nutrition. 2000;16:937-46.
18. Wade GN. Some effects of ovarian hormones on food intake and body weight in female rats. J Comp Physiol Psychol. 1975;88:183-93.
19. Czaja JA, Butera PC, McCaffrey TA. Independent effects of estradiol on water and food intake. Behav Neurosci. 1983;97:210-20.
20. Garcia Rodriguez LA, Pfaff GM, Schumacher MC, Walker AM, Hoffmeister H. Replacement estrogen use and body mass index. Epidemiology. 1990;1:219-23.
21. Wing RR, Matthews KA. Weight gain at the time of menopause. Arch Int Med. 1991;151:97-102.
22. Geary N, Asarian L. Estradiol increases glucagon's satiating potency in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1290-4.
23. Shearer GC, Joles JA, Jones H, Walzern RL, Kaysen GA. Estrogen effects on triglyceride metabolism in analbuminemic rats. Kidney Int. 2000;57:2268-74.
24. Shinoda M, Latour MG, Lavoie JM. Effects of physical training on body composition and organ weights in ovariectomized and hyperestrogenic rats. Int J Obes Relat Merab Disord. 2002;26:335-43.
25. Yoon M, Jeong S, Nicol CJ, et al. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp Mol Med. 2002;34:481-8.
26. Yoon M, Jeong S, Lee H, et al. Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. Biochem Biophys Res Commun. 2003;302:29-34.
27. Jeong S, Kim M, Han M, et al. Fenofibrate prevents obesity and hypertriglyceridemia in LDL receptor-null mice. Metabolism. 2004;53:607-13.
28. Jeong S, Han M, Lee H, et al. Effects of fenofibrate on high fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 2004;53:1283-8.
29. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mot Endocrinol. 1995;9:794-804.
30. Nunez SB, Medin JA, Keller H, et al. Retinoid X receptor beta and peroxisome proliferator-activated receptor activate an estrogen response element. Recent Prog Harm Res. 1995;50: 409-16.
31. Zhu Y, Kan L, Qi C, et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem. 2000;275:13510-6.
32. Nunez SB, Medin JA, Braissant O, et al. Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Endocrinol. 1997;127:27-40.
33. Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP. Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1. J Biol Chem. 2000;275:16302-8.
34. Sinai CJ, Yoon M, Gonzalez FJ. Antagonism of the actions of peroxisome proliferator activated receptor-alpha by bile acids. J Biol Chem. 2001;276:47154-62.
35. Wade GN, Gray JM, Bartness TJ. Gonadal influences on adiposity. Int J Obes. 1985;9:83-92.
36. Asarian L, Geary N. Modulation of appetite by gonadal steroid hormones. Philos Trans R Soc Lond B Biol Sci. 2006;361:1251-63.
37. Tchernof A, Calles-Escandon J, Sites CK, Poehlman ET. Menopause, central body fatness, and insulin resistance: effects of hormone-replacement therapy. Coron Artery Dis. 1998;9:503-11.
38. Nerbrand C, Nyberg P, Nordstrom L, Samsioe G. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides. Maturitas. 2002;42:55-62.
39. Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease: Fibrate Consensus Group. Am J Cardiol. 1998;81:912-7.
40. Lupien PJ, Brun D, Gagne C, Moorjani S, Bielman P, Julien P. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. Can J Cardiol. 1991;7:27-33.
41. Yano T, Kobori S, Sakai M, et al. Beta-very low density lipoprotein induces triglyceride accumulation through receptor mediated endocytotic pathway in 3T3-L1 adipocytes. Atherosclerosis. 1997;135:57-64.
42. Peters JM, Hennuyer N, Staels B, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem. 1997;272:27307-12.
43. Haubenwallner S, Essenburg AD, Barnett BC, et al. Hypo-lipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res. 1995;36:2541-51.
44. Staels B, Vu-Dac N, Kosykh V, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest. 1995;95:705-12.
45. Ma H, Sprecher HW, Kolattukudy PE. Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARgamma-expressing tissue. J Biol Chem. 1998;273:30131-8.
46. Wang X, Kilgore MW. Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol. 2002;194:123-33.
47. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU. An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vilellogenin A2 gene functions in transfected human cells. Cell. 1986;46:1053-61.
48. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992;11:433-9.